Haloperidol (TargetMol, Boston, MA, USA), risperidone (TargetMol), olanzapine (TargetMol), WAY-181187 (oxalate; Tocris Bioscience, Bristol, UK), and SB-742457 (TargetMol) were used in the experiment. Doses of APDs (Haloperidol 0.5 mg/kg, risperidone 0.5 mg/kg, and olanzapine 5 mg/kg) and 5-HT6 ligands (WAY-181187 3 mg/kg and SB-742457 3 mg/kg) were selected for the experiments, based on literature review and our previous studies which presented their separate and combined behavioral effects [54 (link)]. The compounds were suspended in a 1% solution of Tween 80 (Sigma Aldrich, St. Louis, MO, USA) immediately before administration and injected intraperitoneally (ip) in a volume of 2 mL/kg. The compounds were dispensed to the rats once daily between 10:00 and 11:00 a.m. for 28 days. The last injection was given 24 h before sacrifice. The control rats received 1% Tween 80, on the same dosing regimen.
Haloperidol
Manufactured by Targetmol
Sourced in United States
Haloperidol is a butyrophenone-derived antipsychotic drug used as a sedative and antipsychotic medication. It is commonly used to treat various psychiatric disorders, including schizophrenia, mania, and Tourette's syndrome. Haloperidol works by blocking dopamine receptors in the brain, which can help to reduce symptoms such as delusions, hallucinations, and disorganized thinking.
Automatically generated - may contain errors
2 protocols using haloperidol
1
Chronic Effects of APDs and 5-HT6 Ligands
2
Evaluation of Antipsychotic and Selective 5-HT6R Ligands
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The following drugs were used in the study: haloperidol (TargetMol, Boston, MA, USA), risperidone (TargetMol), WAY-181187 (oxalate; Tocris Bioscience, Bristol, UK), and SB-742457 (TargetMol). APDs (haloperidol 0.5 mg/kg and risperidone 0.2 mg/kg) were administered to rats at doses equivalent to the standard ones prescribed for patients with schizophrenia. The equivalent doses were calculated based on the body surface area as described previously by Nair et al.36 (link) Selective 5-HT6R ligands were chosen due to their similar affinity to 5-HT6R (WAY-181187 Ki=2.2 nM22 (link) and SB-742457 Ki=9.6 nM37 (link)), and for comparison reason, these ligands were administered at a dose of 3 mg/kg; ie, a dose at which acute procognitive action for both compounds was observed in our earlier studies.38 (link) The compounds were suspended in a 1% solution of Tween 80 (Sigma Aldrich, UK) before administration and were injected intraperitoneally (ip) in a volume of 2 mL/kg. In the case of acute treatment, haloperidol, risperidone, WAY-181187, and SB-742457 were administered to the rats 60 min before the tests, whereas in the 21-day scheme of treatment, the compounds were administered once a day between 10:00 and 11:00 during 21 consecutive days, with the last injection 24 h before the tests. The control rats were injected with the vehicle according to the same schedule.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!